{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1032.61",
  "meta": {
    "versionId": "9",
    "lastUpdated": "2018-05-09T01:07:38.000-04:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.61",
  "version": "20180509",
  "name": "Immunotherapy",
  "status": "active",
  "date": "2018-05-09T01:00:04-04:00",
  "publisher": "MITRE Steward",
  "compose": {
    "include": [
      {
        "system": "http://www.icd10data.com/icd10pcs",
        "version": "2022",
        "concept": [
          {
            "code": "XW03351",
            "display": "Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1"
          },
          {
            "code": "XW033C3",
            "display": "Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3"
          },
          {
            "code": "XW04351",
            "display": "Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1"
          },
          {
            "code": "XW043C3",
            "display": "Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3"
          }
        ]
      }
    ]
  }
}